IVF Experts call for early implementation of Assisted Reproductive Technology Laws

New Delhi:  Given mindless utilisation of infertility treatments and discard of age factors, fertility experts strongly recommend urgent revisit on Assisted Reproductive Technology (ART) Bill 2017 by the government to properly regulate and monitor it in the country.

Recently a 74-years old woman delivered twins and that alerted the fertility fraternity. As per the Bill —the reproductive technology services shall not be available to a woman below the age of 18 years and above the age of 45 years.

Talking to Medicare News, Dr Archana Dhawan Bajaj, Gynaecologist, Obstetrician and IVF Expert, Nurture IVF Centre says, ‘The government needs urgently to revisit the Bill. Due to a lack of strict regulation through ART laws, we are witnessing a surge in unethical practices and rampant commercialisation of IVF. As an IVF expert, I also strongly recommend that the ART should not be made available to women below the age of 18 and above the age of 45,”

It is a proven fact that women are most fertile between the ages of 15 and 30.

Being most ethical of IVF centres and most vocal about need to regulate the assisted birthing technology, Dr Archana further said, ‘IVF at advanced ages come with risks of pregnancy loss, fetal anomalies, stillbirth, and obstetric complications. It is also associated with medical comorbidities in mother due to increasing maternal age like hypertension, diabetes and heart problem. It poses risks to both mother and child.’

The Indian Fertility Society (IFS) has also condemned the mindless misutilization of IVF technologies.

Appealing all its members and health professionals to abstain from such unethical malpractice which may risk the lives of the patients, offsprings and future generation, Dr. Pankaj Talwar, Secretary General IFS, said, ‘We, as reproductive health professionals, have a great responsibility towards society and couples. The ART should not be made available to women below the age of 18 and above the age of 45.’

In India, currently, there is no prohibition on the ART above 45 years of age or below 18 years.

Dr. Anoop Gupta from Delhi IVF Fertility Research Centre said, ‘The Assisted Reproductive Technology (ART) has come as a boon for infertility treatment. However, this needs to utilise ethically and we need to keep both the health and social aspects of the patient in mind. I strongly recommend that the ART should be available to a woman above the age of eighteen years and below the age of forty-five years.’

The Indian Council of Medical Research (ICMR) has been making efforts to put in place regulations and had drafted the ART Bill. Fertility experts expect that now ICMR would take urgent action to once again re-introduce the Bill in Parliament.

Related Posts

Medicines that cure Us are making Our Environment Sick

Antimicrobial Resistance Campaigner makes a Fervent Appeal for Safe Disposal of Leftover Medicines New Delhi: We invariably worry about what might be the side effects of medicines on our body…

ZEN- G packs a punch in Organ Donation as Over 500 Students pledge Organs

National Organ Transplant Games2026 set World Record in Talkatora Indoor Stadium New Delhi: The National Organ Transplant Games began on a high note in Talkatora Indoor Stadium on November 1,…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels

From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels

UP expands food, drug testing capacity across all 18 divisions

UP expands food, drug testing capacity across all 18 divisions

Abbott receives US FDA approval and CE Mark for the UltiSynq defibrillation lead

Abbott receives US FDA approval and CE Mark for the UltiSynq defibrillation lead

Medicines worth ₹14 lakh seized from unlicensed residential premises in Delhi

Medicines worth ₹14 lakh seized from unlicensed residential premises in Delhi